Asian Stocks Fall as Oil Tops $100, Yields Rise 
Gold Prices Steady Ahead of U.S. Inflation Data and Fed Decision 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
TSMC August Revenue Jumps 53% on AI Chip Demand 
UK Businesses Urge Government to Cut Electricity Levies 
Can Europe shake its Russia links for good? 
Huawei Launches Mate XT2 Foldable Phone in China 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
OpenAI Agents Used Websites for Unauthorized Communications 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
Australia Plans New Rules Giving Users Control Over Social Media Feeds 
Kioxia Rules Out SK Hynix Manufacturing Partnership 
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
Fitch Eyes Japan Budget for Fiscal Discipline 
German Inflation Accelerates to 2.9% in August 
Qualcomm Stock Jumps on Amazon AI Chip Deal 
Add as a preferred source on Google
NGeneBio, a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx) in South Korea, announced it had established its new subsidiary in the United States. The company said on Monday, July 24, it has set up an artificial intelligence (AI) precision diagnostic firm called NGeneBioAI.
NGeneBio formed this company to tap into the U.S. precision diagnosis market. The plan is to earmark the data-driven cancer genomic diagnostics market in the country through its own precision diagnostic software.
According to The Korea Economic Daily, the formation of NGeneBioAI was fully funded by NGeneBio, which is now standing as its parent company. Its US subsidiary is now expected to play a big role in NGeneBio’s entry into the region’s cancer diagnostics market. It will offer its next-generation sequencing (NGS) precision diagnostic platform as it starts to build its presence in the American market.
Moreover, in addition to services related to cancer data analysis, NGeneBio will also initiate healthcare data analysis technology. The company will create AI-based diagnostic software with the aim of commercializing data-driven early cancer diagnosis apparatus.
“NGENBIO’s precise diagnosis SW technology is being evaluated as excellent in performance and quality by clinicians to the extent that it is being used in clinical trials for cancer patients at domestic and foreign medical institutions,” NGeneBio’s chief executive officer, Choi Dae Chul explained in a press release.
The CEO added, “With the establishment of NGENBIO AI, we will increase the accuracy of cancer precision diagnosis by expanding NGENBIO SW to the US medical market, and speed up the ongoing strategic investment in the CLIA Lab to complete within the year.”
Finally, Korea Biomedical Review reported that the supply of the company’s NGS precision diagnosis product line will also start in earnest via partnership deals with Clinical Laboratory Improvement Amendments (CLIA) Labs in the U.S.
Photo by: NGeneBio Website
